- Home
- AIM vs NCRA Comparison
AIM vs NCRA Comparison
Compare AIM & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- NCRA
- Stock Information
- Founded
- AIM 1966
- NCRA 2002
- Country
- AIM United States
- NCRA Taiwan
- Employees
- AIM N/A
- NCRA N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- NCRA Farming/Seeds/Milling
- Sector
- AIM Health Care
- NCRA Consumer Staples
- Exchange
- AIM Nasdaq
- NCRA Nasdaq
- Market Cap
- AIM 15.9M
- NCRA 15.4M
- IPO Year
- AIM N/A
- NCRA N/A
- Fundamental
- Price
- AIM $0.22
- NCRA $1.00
- Analyst Decision
- AIM Strong Buy
- NCRA
- Analyst Count
- AIM 2
- NCRA 0
- Target Price
- AIM $3.00
- NCRA N/A
- AVG Volume (30 Days)
- AIM 295.4K
- NCRA 17.6K
- Earning Date
- AIM 11-15-2024
- NCRA 08-14-2024
- Dividend Yield
- AIM N/A
- NCRA N/A
- EPS Growth
- AIM N/A
- NCRA N/A
- EPS
- AIM N/A
- NCRA N/A
- Revenue
- AIM $190,000.00
- NCRA $20,483,694.00
- Revenue This Year
- AIM N/A
- NCRA N/A
- Revenue Next Year
- AIM $1,086.80
- NCRA N/A
- P/E Ratio
- AIM N/A
- NCRA N/A
- Revenue Growth
- AIM N/A
- NCRA N/A
- 52 Week Low
- AIM $0.21
- NCRA $0.73
- 52 Week High
- AIM $0.62
- NCRA $1.54
- Technical
- Relative Strength Index (RSI)
- AIM 35.93
- NCRA 43.45
- Support Level
- AIM $0.24
- NCRA $0.99
- Resistance Level
- AIM $0.27
- NCRA $1.10
- Average True Range (ATR)
- AIM 0.02
- NCRA 0.12
- MACD
- AIM -0.00
- NCRA -0.02
- Stochastic Oscillator
- AIM 7.49
- NCRA 9.79
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with expert consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.